Bioventus Posts 500-Basis-Point EBITDA Margin Expansion, Q4 Cash Hits $38 Million
Bioventus expanded its Q4 adjusted EBITDA margin by nearly 500 basis points and generated a record $38 million in quarterly operating cash, aided by refinancing that reduced interest expenses and improved inventory management. It forecasts 2026 cash flows of $82–87 million, a 10–17% increase.
1. Q4 Financial Performance
Bioventus reported a 26% revenue decline in Restorative Therapies after divesting its Advanced Rehabilitation business and a 3% revenue gain in Surgical Solutions versus prior year, while an unfavorable foreign exchange impact cost nearly $1 million. The company expanded its adjusted EBITDA margin by 500 basis points and achieved record quarterly cash from operations of $38 million, driven by strong commercial execution and inventory management.
2. Refinancing and Liquidity Enhancement
During Q4, Bioventus refinanced its term loan, lowering interest expenses and bolstering liquidity for 2026. Improved inventory practices further accelerated cash generation, positioning the company to fund strategic investments without increasing leverage.
3. 2026 Guidance and Growth Drivers
Management forecasts 2026 operating cash flow of $82–87 million, up 10–17%. Segment assumptions include low- to mid-single-digit growth in Restorative Therapies, mid- to high-single-digit growth in Pain Treatments, and double-digit growth in Surgical Solutions. The company expects at least 200 basis points of total growth from new initiatives in Peripheral Nerve Stimulation and Platelet-Rich Plasma.